Aethlon Medical, Inc. (AEMD) Analysts See $-0.08 EPS

July 13, 2018 - By Andrea Pope

Aethlon Medical, Inc. (NASDAQ:AEMD) Logo

Analysts expect Aethlon Medical, Inc. (NASDAQ:AEMD) to report $-0.08 EPS on August, 9.They anticipate $0.13 EPS change or 61.90 % from last quarter’s $-0.21 EPS. After having $-0.06 EPS previously, Aethlon Medical, Inc.’s analysts see 33.33 % EPS growth. It closed at $1.3 lastly. It is down 33.15% since July 14, 2017 and is downtrending. It has underperformed by 45.72% the S&P500.

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company has market cap of $23.09 million. The firm is developing Aethlon Hemopurifier, a clinical-stage therapeutic device for the single-use removal of life-threatening viruses from the circulatory system of infected individuals. It currently has negative earnings. It is also involved in the development of exosome products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection.

Another recent and important Aethlon Medical, Inc. (NASDAQ:AEMD) news was published by which published an article titled: “New Research: Key Drivers of Growth for Nicolet Bankshares, Vitamin Shoppe, Aethlon Medical, Barrett Business …” on June 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.